Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom

Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom

Currently, the 13-valent pneumococcal conjugate vaccine (PCV13) is administered under a 1+1 (1 primary dose) pediatric schedule in the United Kingdom (UK). Higher-valency PCVs, 15-valent PCV (PCV15), or 20-valent PCV (PCV20) might be considered to expand serotype coverage. We evaluated the cost-effe...

Full description

Bibliographic Details
Main Authors: Michele Wilson, Aaron Lucas, Diana Mendes, Andrew Vyse, Boglarka Mikudina, Carole Czudek, Gillian Frances Ellsbury, Johnna Perdrizet
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Vaccines
Subjects:
pneumococcal disease
vaccines
cost-effectiveness
pneumococcal vaccination
economics
Online Access:https://www.mdpi.com/2076-393X/11/7/1168

Internet

https://www.mdpi.com/2076-393X/11/7/1168

Similar Items